Sartorius Stedim Biotech Reports on Share and Voting Rights Composition

Sartorius Stedim Biotech SA, headquartered in Aubagne, France, has released its statement concerning the composition of its issued capital as of September 30, 2026. This declaration is based on Article L 233-8-II of the French Code of Commerce and Article 223-6 of the AMF general regulations.

As reported, the total number of shares making up the issued capital stands at 97,330,405. The theoretical voting rights, including treasury shares, amount to 164,770,938, while the net voting rights are slightly lower, totaling 164,752,145. These figures reflect the company's capital structure as disseminated by EQS Group.

This announcement is part of Sartorius Stedim Biotech’s regulatory obligations to provide transparency regarding its share and voting right status, ensuring stakeholders are informed of any changes.